| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Gain on exercise of warrant liabilities | 5,369 | - | ||
| Total other expense (income) | -1,866 | -13,851 | ||
| Net loss | -5,890 | -17,581 | ||
| Change in fair value of convertible note attributed to credit risk | 0 | - | ||
| Other comprehensive loss | 0 | - | ||
| Comprehensive loss | -5,890 | - | ||
| Basic and diluted (in dollars per share) | -0.27 | -0.98 | ||
| Basic and diluted (in shares) | 22,231,178 | 17,934,196 | ||
NRX Pharmaceuticals, Inc. (NRXP)
NRX Pharmaceuticals, Inc. (NRXP)